Skip to content
PeptideHormone

Two families, one syringe

EloraTZP is Lilly’s name for eloralintide given with tirzepatide: a selective amylin agonist stacked on a dual GIP/GLP-1 agonist, two satiety families in one co-formulation. In a 48-week phase 2b trial in obesity with type 2 diabetes, reported at EASD in September 2026, the top combination reached 23.3% mean weight loss versus 14.8% on tirzepatide 15 mg alone. The arithmetic is less than fully additive, discontinuation for adverse events ran as high as 27% on a combination arm, and the result is still a press release, not a paper. Why the stack is a third answer after CagriSema and amycretin, what the numbers actually say, and what phase 3 has to survive. Bullish on the science, sceptical on the page.

9 min read · reviewed November 2026

The name is a stack, not a molecule

EloraTZP is not a new peptide. It is Lilly’s label for eloralintide given together with tirzepatide: a selective amylin receptor agonist stacked on a dual GIP and GLP-1 receptor agonist. In the phase 2b study the two drugs were separate once-weekly injections. The product Lilly says it will take into phase 3 is a co-formulation — one syringe, two molecules, each keeping its own pharmacokinetics.

That design is the point. Amycretin welds GLP-1 and amylin into one chain and fixes the ratio. CagriSema is two pens of cagrilintide plus semaglutide. EloraTZP is the third answer: two satiety families, independently engineered, mixed rather than fused. A two-week amylin analog and a five-day dual incretin in the same injection is a mixture, not a molecule.

The reframe

The 23% headline is not “amylin beat tirzepatide.” It is tirzepatide plus a second receptor family, in the harder population — obesity with type 2 diabetes — where every class loses less weight.

What the 48-week readout actually said

Lilly randomised 367 adults with obesity and type 2 diabetes across ten arms for 48 weeks and reported at EASD in Milan on 30 September 2026. It is a press release and a conference presentation; the paper has not been published (Lilly, 30 September 2026, PR Newswire, NCT06603571). Combination arms started at eloralintide 1 or 3 mg plus tirzepatide 2.5 mg and escalated every four weeks to target.

Placebo−3%Elora 9 mg−11.1%TZP 15 mg−14.8%Elora 6 + TZP 10−19.9%Elora 9 + TZP 15−23.3%
Mean percent body-weight change at 48 weeks, EloraTZP phase 2b (Lilly release, EASD 2026). Not a published primary analysis.
  • The headline. Eloralintide 9 mg plus tirzepatide 15 mg: −23.3% body weight (~54.1 lb) and −2.9 A1C points. Tirzepatide 15 mg alone: −14.8% and −2.4. Eloralintide 6 mg plus tirzepatide 10 mg: −19.9%. Placebo: −3.0%.
  • Eloralintide alone, this population. In people with type 2 diabetes, weekly eloralintide reached −8.2% at 3 mg, −12.3% at 6 mg, −11.1% at 9 mg. That is not the 20% from the obesity-without-diabetes monotherapy trial (The Lancet, December 2025; PMID 41207310). Diabetes is the harder room.
  • The arithmetic. The top combination beat tirzepatide 15 mg by 8.5 points of weight. Eloralintide alone contributed about 11 to 12 points here. Less than fully additive — two satiety signals converging on overlapping hindbrain circuits would predict that — and still the largest number reported in this population to date. Do not rank it against retatrutide: there is no head-to-head.
  • The cost. Discontinuation for adverse events ran 10.8% to 27.0% on combination arms, against 2.9% on tirzepatide alone and 0% to 10.8% on eloralintide alone. Gastrointestinal events were more frequent on the stack. Lilly attributes this to escalation and promises an optimised schedule for phase 3.
  • The odd placebo. Placebo discontinuation was 16.7%, higher than most active arms, and placebo weight loss was 3.0%. Neither is explained in the release.

The 20% monotherapy figure that gets compared in passing is a different trial, a different population, and a published paper (PMID 41207310). EloraTZP’s 23.3% is still a release.

Three ways to put amylin next to an incretin

The field is not short of combination ideas. It is short of a ranking among them.

  • CagriSema — two pens. Cagrilintide (dual amylin and calcitonin receptor agonist) plus semaglutide. Ratio can, in principle, be tuned. Two injections, two manufacturing paths.
  • Amycretin — one chain. GLP-1 and amylin agonism welded into a single peptide. One pharmacokinetic profile, one titration — and a GLP-1-to-amylin ratio that cannot be dialled.
  • EloraTZP — one syringe, two molecules. Selective amylin agonist plus tirzepatide (GIP/GLP-1). Co-formulation keeps each half-life; phase 2b still used two pens. The incretin half is already the dual agonist, not semaglutide.

Eloralintide’s monotherapy case — 20% at 48 weeks with no GLP-1 receptor in the molecule — is told in The note without the incretin. This page is the stack: whether that amylin note is worth adding to the best incretin Lilly already sells.

What phase 3 has to survive

Lilly says phase 3 of a co-formulated EloraTZP begins in Q4 2026. Until those trials enroll, report, and publish, the honest label is a conference topline in 367 people.

  • Tolerability at scale. A 27% discontinuation arm is not a rounding error. An 'optimised escalation' is a hypothesis, not a result.
  • The paper. Estimands, missing-data handling, which arm hit 27%, and whether the 8.5-point gap survives the primary analysis — none of that is in a press release.
  • Co-formulation is not two pens. Phase 2b mixed two injections. Phase 3 of one product has to show the mixture still behaves when the two peptides share a vial.
  • No league table. 23.3% in type 2 diabetes is not a ranking against retatrutide, CagriSema, or amycretin. Different populations, different durations, no shared control.
Until then

EloraTZP has shown that stacking a selective amylin agonist on tirzepatide can move weight and A1C past tirzepatide 15 mg in type 2 diabetes. It has not shown that the stack is livable, publishable, or better than the other two ways of putting amylin next to an incretin.

Common questions

What is EloraTZP?
EloraTZP is Eli Lilly's investigational combination of eloralintide, a once-weekly selective amylin receptor agonist, and tirzepatide, a dual GIP and GLP-1 receptor agonist (the active ingredient in Mounjaro and Zepbound). In the phase 2b trial the two drugs were given as separate weekly injections; Lilly plans phase 3 of a single co-formulated product by the end of 2026. Neither the combination nor eloralintide is approved.
How much weight did people lose on EloraTZP vs tirzepatide?
In a 48-week phase 2b trial of 367 adults with obesity and type 2 diabetes, reported at EASD on 30 September 2026, eloralintide 9 mg plus tirzepatide 15 mg produced a mean 23.3% weight loss (about 54.1 lb) and a 2.9-point A1C reduction, versus 14.8% and 2.4 points on tirzepatide 15 mg alone. Eloralintide 6 mg plus tirzepatide 10 mg reached 19.9%. Eloralintide alone in this diabetic population reached at most 12.3% (6 mg). The result is a sponsor release and conference presentation; the paper has not been published.
When does EloraTZP enter phase 3?
Lilly said, based on this 48-week phase 2b, it will initiate phase 3 trials of an EloraTZP co-formulation in Q4 2026, using an optimized escalation schedule. Eloralintide monotherapy is already in phase 3 for obesity (the ENLIGHTEN program). A press-release timeline is not enrollment; check ClinicalTrials.gov for the combination studies when they post.
Is EloraTZP the same as CagriSema or amycretin?
No. CagriSema is Novo's two-pen stack of cagrilintide (a dual amylin/calcitonin agonist) plus semaglutide. Amycretin is Novo's unimolecular GLP-1-plus-amylin peptide. EloraTZP is Lilly's two-molecule stack of a selective amylin agonist plus tirzepatide (GIP/GLP-1), intended as one co-formulated injection. Three answers to the same question — two satiety families — with different chemistry, different incretin half, and no head-to-head.
Why did so many people discontinue EloraTZP?
Treatment discontinuation for adverse events was 10.8% to 27.0% across EloraTZP arms, versus 2.9% on tirzepatide 15 mg, 0% to 10.8% on eloralintide alone, and 16.7% on placebo. Gastrointestinal events were the most common and were more frequent on the combination. The release attributes this to the escalation used in the trial and promises a different schedule for phase 3. A 27% arm is the number to watch when the paper appears; placebo discontinuation being higher than most active arms is unexplained in the release.

Educational reference on mechanism, summarized from public scientific literature and clinical-trial disclosures and simplified in places. Not individualized medical advice or a prescription. Where a dose or regimen appears it is reported from its source as research literacy — so you can read the evidence yourself — not an instruction to dose. Investigational, not approved: eloralintide and EloraTZP. Approved in the United States: tirzepatide. Status checked November 2026. Specific compounds and trials are named to explain the science; verify any claim against the linked primary sources.